Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 1,458

Document Document Title
WO/2021/069570A1
Compounds and compositions for the activation of SERCA2a are disclosed. In particular, provided are compounds that act as predominantly pure or pure SERCA2a activators while only moderately inhibiting the Na+/K+ ATPase. In general, the d...  
WO/2021/041896A1
The present disclosure provides compositions and methods for the detection and treatment of cancer. Specifically, the compositions of the present technology include novel radiohalogenated (e.g., radioiodinated) PSMA targeting agents and ...  
WO/2021/027306A1
Disclosed is a conjugate obtained by condensing dihydroartemisinin and a steroid, as represented by the following general formula (I), or an isomer, pharmaceutically acceptable salt, or prodrug molecule thereof; wherein the hydroxy group...  
WO/2021/023213A1
The present invention relates to a steroid derivative regulator, in particular to a compound of formula (I), a salt and crystal form thereof, a preparation method therefor, a pharmaceutical composition containing a therapeutically effect...  
WO/2020/259612A1
Disclosed in the present invention are a compound represented by general formula I, a pharmaceutically acceptable salt, solvate, or stereoisomeride containing mixtures at different ratios thereof, and a pharmaceutical composition contain...  
WO/2020/264512A1
Provided herein in part is a compound of Formula (I): or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising a compound of Formula I, and methods of using the compounds, e.g, in the treatment of CNS- relate...  
WO/2020/264495A1
Provided herein is a compound of Formula (1-I): or a pharmaceutically acceptable salt thereof, wherein R2a, R2b, R3, R4a, R4b, R5, R6a, R6b, R11a, R11b, R16a, R16b, R19, R18, X, q, r, s, t, u, and n are defined herein. Also provided here...  
WO/2020/242772A1
The present disclosure encompasses solid state forms of SAGE-217, in embodiments SAGE-217: Oxalic acid Co-crystal, processes for preparation thereof, and pharmaceutical compositions thereof.  
WO/2020/243488A1
Provided herein is a compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein R1a, R1b, R2a, R2b, R3, R4a, R4b, R5, R6a, R6b, R7a, R7a, R11a, R11b, R12a, R12b, R16a, R16b, R19, R11a, R22, RX, RY and n are defined he...  
WO/2020/210116A1
The invention provides steroid compounds with altered pharmacological properties and methods of using the compounds to treat a condition in a subject.  
WO/2020/200335A1
The invention provides 3α5β–steroid compounds of general formula I. These compounds are useful in the treatment of epilepsy or comorbidities associated with epilepsy or conditions associated with convulsions, such as seizures associa...  
WO/2020/180942A1
Sustained-release abiraterone prodrug formulations, methods, and kits for parenteral administration to a subject having a sex hormone-dependent benign or malignant disorder such as prostate cancer, a syndrome due to androgen excess, and/...  
WO/2020/172655A1
Provided are compounds, which may be referred to as PHOTACs (photoswitchable proteolysis targeting chimeras), and compositions, kits, and methods of making and using PHOTACs. PHOTACs have one or more E3 ligase ligand(s), one or more phot...  
WO/2020/163026A1
Unusual and unexpectedly stable aqueous suspension formulation and water dispersible dry composition of the following formula (I) compounds. It causes little or no injection site irritation and has superior properties over non-aqueous fo...  
WO/2020/146541A3
Provided herein are compounds, compounds including traceless linkers, protein conjugates thereof, and compositions thereof. Also provided herein are methods for the treatment of diseases, disorders, and conditions, and/or the management ...  
WO/2020/147852A1
The present application relates to crystal form 04, crystal form 06, crystal form D-1, and crystal form D-2 of an antidepressant drug SAGE-217 and a preparation method therefor and a pharmaceutical composition containing same. The XRPD o...  
WO/2020/146541A2
Provided herein are compounds, compounds including traceless linkers, protein conjugates thereof, and compositions thereof. Also provided herein are methods for the treatment of diseases, disorders, and conditions, and/or the management ...  
WO/2020/135454A1
Provided in the present invention are compounds of formulae (I), (II), (III) and (IV), a stereoisomer, a tautomer or a pharmaceutically acceptable salt thereof. Disclosed are a method for preparing such compounds and the use of the compo...  
WO/2020/132504A1
Provided herein is a compound of Formula (I) or pharmaceutically acceptable salt thereof, wherein R2a, R2b, R4a, R4b, R6, R7, R11a, R11b, R16, R17, R3, R5, R19 and RX are defined herein and wherein RY represents optionally substituted he...  
WO/2020/128514A1
2-Fluorinated bile acid compounds of general formula (I) wherein at least one of R1 and R2 represents F and the other is chosen 3 from H and F and wherein R3 is as defined herein; are of use in the treatment and prevention of neurodegene...  
WO/2020/131918A1
The invention relates to particular prodrugs and analogs of (3α,5α)-3-hydroxy-21-(1H-imidazol-1-yl)-3-methoxymethyl)-p regnan-20-one, in free or pharmaceutically acceptable salt and/or substantially pure form as described herein, pharm...  
WO/2020/124094A1
The invention relates to methods of treating depression with Compound 1 or pharmaceutically acceptable salts thereof. The present disclosure, among other things, provides methods of treating depression by administering a therapeutically ...  
WO/2020/115371A1
The invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof (I) wherein R1 to R4 are as defined in the claims. The invention further relates to their use as inhibitors of 17β-HSD1 and in treatment or ...  
WO/2020/118060A1
Provided herein is a compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein R19, R5, R3a, R1a, R1b, R2 a, R2 b, R4 a, R4 b, R6a, R6b, R7a,R7b,R11a, R11b, R12a,R12b, R18, RD, and q are defined herein. L is selected...  
WO/2020/082065A1
Provided herein is a compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein n, R19, R5, R3, R6a, R6b, R2a, R2b, R4a, R4b, R7a, R7b, R11, R12a, R12b, R16, R21a, R21b, and R21c are defined herein. Also provided here...  
WO/2020/077255A1
Provided herein is a compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein n, R19, R5, R3a, R6a, R6b, R1, R2a, R2b, R4a, R4b, R7a, R7b, R11a, R11b, R12a, R12b, R17b, R15a, R15b, R16a and R16b are defined herein. ...  
WO/2020/020728A1
Disclosed are compounds of formula (I), wherein X, Y, Z are annular atoms comprised in a five-membered carbocyclic or heterocyclic ring, selected from the group consisting of CH, NH, N, O, S; saidcarbocyclic or heterocyclic ring being op...  
WO/2020/018893A1
Compounds of formula: are described herein. The compounds selectively complex copper and are therefore useful both abiotically for measuring and detecting small amounts of copper and, in biological systems, for treating diseases associat...  
WO/2020/015659A1
Provided is a method for refining crude rocuronium bromide; the method comprises: using vacuum microwave drying or fluidized drying to remove residual solvent in crude rocuronium such that same meets medicinal requirements. Using the met...  
WO/2019/211705A1
A modified small molecule of general formula (I) or (II) or various forms thereof which can be used for selective detection of non-pathogenic, pathogenic, drug-sensitive, drug-resistant, live/dead, persistent, stationary, metabolically-i...  
WO/2019/186444A1
The present invention relates to liquid formulations of Abiraterone intended for oral administration. The invention provides suspension and emulsion fom1ulations of Abiraterone and process of preparing such formulations. Further, the inv...  
WO/2019/177099A1
Provided is a method for evaluating a test sample, said method making it easy to evaluate whether a test sample has the effect of suppressing cytokine production in skin cells, wherein the cytokine production suppressing effect of the te...  
WO/2019/177902A1
The present disclosure relates to bifunctional compounds, which find utility as modulators of Burton's Tyrosine Kinase (BTK). In particular, the present disclosure is directed to bifunctional compounds. One end of a bifunctional compound...  
WO/2019/160889A1
Compounds of Formula (I) or pharmaceutically acceptable salts thereof are provided and methods involving compounds of Formula (I) as effective inhibitors of CDK8 and/or CDK19 are also provided.  
WO/2019/160890A1
The present application provides bifunctional compounds of Formula (Ia): (Ia), or an enantiomer, diastereomer, stereoisomer, or pharmaceutically acceptable salt thereof, which act as protein degradation inducing moieties for one or more ...  
WO/2019/154257A1
The present invention relates to steroid derivative regulators, a method for preparing the same, and uses thereof. Specifically, the present invention relates to a compound of formula (I), a preparation method therefor, a pharmaceutical ...  
WO/2019/154247A1
The present invention relates to steroid derivative regulators, a method for preparing the same, and uses thereof. Specifically, the present invention relates to a compound as shown in formula (I), a preparation method therefor, a pharma...  
WO/2019/126741A1
Provided herein are compounds of Formula (I-I): and pharmaceutically acceptable salts thereof; wherein p, R1, R3a, R2a, R11a, R11b, R6a, and R6b are defined herein. Also provided herein are pharmaceutical compositions comprising a compou...  
WO/2019/113494A1
Provided herein is a deuterated compound of Formula (I) Formula (I) or a pharmaceutically acceptable salt thereof, wherein R3a,R5, R6a, R6b, R17, R21a, R21b, Rm, Rn, R16a, R16 b, R7a, R7b, R12a, R12b, R11a R11b, R2a, R2b, R19, R4a, and R...  
WO/2019/090331A1
Provided is a method of forming a copper-containing complex, including contacting a sample containing copper with a compound of Formula (I): wherein R is -OH or -O-CH3. Also provided is a method of inhibiting enzymatic activity of a kina...  
WO/2019/020068A8
Disclosed are a crystalline or amorphous form of steroid derivative FXR agonist (formula I), and a preparation method therefor, and a crystalline composition and pharmaceutical composition comprising the crystalline or amorphous form, an...  
WO/2019/062924A1
Provided are a long-acting prodrug of entecavir and a preparation method and application thereof. The prodrug of entecavir has the structure shown in formula I, and the compound can be released slowly, continuously, and stably and conver...  
WO/2019/020067A1
The present invention falls within the field of pharmaceutical chemistry, and relates to a method for preparing a steroid derivative FXR agonist and the relevant intermediates. In particular, the present invention relates to a method for...  
WO/2019/020068A1
Disclosed are a crystalline or amorphous form of steroid derivative FXR agonist (formula I), and a preparation method therefor, and a crystalline composition and pharmaceutical composition comprising the crystalline or amorphous form, an...  
WO/2018/224736A3
The invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof wherein Rl to R4 are as defined in the claims. The invention further relates to their use as inhibitors of 17P-HSD1 and in treatment or preve...  
WO/2019/002015A1
The invention relates to novel steroidal 17-beta heteroaryl compounds as AKR1C3 inhibitors, to the use thereof for the treatment and/or prophylaxis of diseases and to the use thereof for the production of medicaments for treatment and/or...  
WO/2018/237350A1
The present disclosure relates to methods and novel intermediates useful in the preparation of a compound of formula I or pharmaceutically acceptable salt, hydrate, solvate or amino acid, sulfate or glucuronide conjugate, or prodrug ther...  
WO/2018/224736A2
The invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof (I) wherein R1 to R4 are as defined in the claims. The invention further relates to their use as inhibitors of 17β-HSD1 and in treatment or ...  
WO/2017/205964A8
Estrane-based and androstane-based aminosteroid derivatives are described herein. More specifically, the following piperazinyl-steroid compounds of Formula I, Formula II, Formula III, and Formula IV are described. The compounds display c...  
WO/2018/152171A1
The present invention provides compounds represented by Formula I, or pharmaceutically acceptable salts, prodrugs and esters thereof, (I). The invention also provides pharmaceutical compositions comprising these compounds and methods of ...  

Matches 1 - 50 out of 1,458